Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.

Abstract

OBJECTIVE:

Tafasitamab, loncastuximab, tesirine, polatuzumab, and selinexor have been proposed for the treatment of relapsed/refractory B-cell lymphomas. We studied the patterns of overall survival (OS) for these four agents. PATIENTS  AND METHODS: We reconstructed patient-level data from the published Kaplan-Meier OS graphs. For this purpose, we used an artificial intelligence technique (the Shiny method). Reconstructed survival curves were then subjected to standard statistics to perform between-treatment comparisons, and hazard ratios (HRs) and 95% confidence intervals (CI) were estimated.

RESULTS:

Using tafasitamab plus lenalidomide as a common comparator, our analysis of OS yielded the following results: a) Polatuzumab vedotin vs. tafasitamab + lenalidomide: HR=1.60 (95%CI, 0.94-2.74, p=0.0831); b) Selinexor vs. tafasitamab + lenalidomide: HR=2.28 (95%CI, 1.54-3.38, p<0.001); c) Loncastuximab tesirine vs. tafasitamab + lenalidomide: HR=2.35 (95%CI, 1.55-3.56, p<0.001). All three values favored tafasitamab + lenalidomide.

CONCLUSIONS:

These comparative OS results represent the original findings. Although these comparisons were indirect, our analysis offered a useful synthesis of the outcomes reported thus far for these four treatments.

• Authors: A Messori, E Caccese
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 26 Issue 13 Pg. 4666-4670 (07 2022) ISSN: 2284-0729 [Electronic] Italy
• PMID: 35856357 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Lenalidomide

Topics

• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Artificial Intelligence
• Humans
• Lenalidomide (therapeutic use)
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• Lymphoma, Non-Hodgkin (drug therapy)